Search Results

Applied Energetics, Inc. today announced that Dr. James Harrison has been named director of new product innovation for the company, effective April 3, 2024.

Applied Energetics, Inc., a leader in the advancement of ultrashort pulse laser, announced that Dr. Stephen W. McCahon, age 63, has been appointed as Chief Science Officer, effective May 1, 2023.

The agency’s warning letter outlines Applied Therapeutics’ failure to provide adequate information regarding the clinical trial—including a dosing error for govorestat—claims that the company said it had already addressed.

Applied Energetics, Inc. announced that it has been awarded a $1.148 million Phase II Small Business Technology Transfer contract by the U.S Army to continue the Company’s research, development and testing of an ultra-broadband infrared source capable of disrupting optical infrared sensors within the engagement time window, at tactically relevant ranges.

After extending its review period to evaluate additional submissions, the FDA ultimately denied Applied Therapeutics’ govorestat for galactosemia, citing “deficiencies” with the application. The biotech plans to meet with the regulator to discuss the best way forward for the drug.

Applied UV, Inc. (NASDAQ: AUVI) (the “Company”), a leader in smart building technology solutions, today announced the closing of its previously announced registered direct offering and concurrent private placement with institutional investors.